265 related articles for article (PubMed ID: 2818657)
1. Factor B activation products in patients with systemic lupus erythematosus. A marker of severe disease activity.
Kerr LD; Adelsberg BR; Schulman P; Spiera H
Arthritis Rheum; 1989 Nov; 32(11):1406-13. PubMed ID: 2818657
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity.
Manzi S; Rairie JE; Carpenter AB; Kelly RH; Jagarlapudi SP; Sereika SM; Medsger TA; Ramsey-Goldman R
Arthritis Rheum; 1996 Jul; 39(7):1178-88. PubMed ID: 8670328
[TBL] [Abstract][Full Text] [Related]
3. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy.
Buyon JP; Tamerius J; Ordorica S; Young B; Abramson SB
Arthritis Rheum; 1992 Jan; 35(1):55-61. PubMed ID: 1731815
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of alternative pathway and factor B haemolytic activities in patients with systemic lupus erythematosus: correlations with the alternative pathway regulatory proteins.
Aguado MT; Perrin LH; Ramirez R; Miescher PA; Lambert PH
Clin Exp Immunol; 1980 Dec; 42(3):495-505. PubMed ID: 6163579
[TBL] [Abstract][Full Text] [Related]
5. Increased amounts of C4-containing immune complexes and inefficient activation of C3 and the terminal complement pathway in a patient with homozygous C2 deficiency and systemic lupus erythematosus.
Garred P; Mollnes TE; Thorsteinsson L; Erlendsson K; Steinsson K
Scand J Immunol; 1990 Jan; 31(1):59-64. PubMed ID: 2300790
[TBL] [Abstract][Full Text] [Related]
6. Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus.
Senaldi G; Makinde VA; Vergani D; Isenberg DA
Ann Rheum Dis; 1988 Nov; 47(11):913-7. PubMed ID: 3264693
[TBL] [Abstract][Full Text] [Related]
7. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
Mayes JT; Schreiber RD; Cooper NR
J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
[TBL] [Abstract][Full Text] [Related]
8. Relative importance of C3b inactivator and beta 1H globulin in the modulation of the properdin amplification loop in systemic lupus erythematosus.
Whaley K; Schur PH; Ruddy S
Clin Exp Immunol; 1979 Jun; 36(3):408-14. PubMed ID: 114347
[TBL] [Abstract][Full Text] [Related]
9. Activation of factor B of the alternative pathway of complement. Assessment by rocket immunoelectrophoresis.
Kajdacsy-Balla A; Doi EM; Bagasra O
Am J Clin Pathol; 1987 Jul; 88(1):66-73. PubMed ID: 3649166
[TBL] [Abstract][Full Text] [Related]
10. Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus.
Röther E; Lang B; Coldewey R; Hartung K; Peter HH
Clin Rheumatol; 1993 Mar; 12(1):31-5. PubMed ID: 8467609
[TBL] [Abstract][Full Text] [Related]
11. A novel ELISA for the assessment of classical pathway of complement activation in vivo by measurement of C4-C3 complexes.
Zwirner J; Dobos G; Götze O
J Immunol Methods; 1995 Oct; 186(1):55-63. PubMed ID: 7561148
[TBL] [Abstract][Full Text] [Related]
12. Utilization of complement testing in clinical medicine.
Abdul-Aziz K; Faizal AA
Saudi Med J; 2006 Nov; 27(11):1775-7. PubMed ID: 17106567
[No Abstract] [Full Text] [Related]
13. Complement activation before, during and after cardiopulmonary bypass.
Bonser RS; Dave JR; John L; Gademsetty MK; Carter PG; Davies E; Taylor P; Gaya H; Lennox SC; Vergani D
Eur J Cardiothorac Surg; 1990; 4(6):291-6. PubMed ID: 2361017
[TBL] [Abstract][Full Text] [Related]
14. Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus.
Ramsey-Goldman R; Alexander RV; Massarotti EM; Wallace DJ; Narain S; Arriens C; Collins CE; Saxena A; Putterman C; Kalunian KC; O'Malley T; Dervieux T; Weinstein A
Arthritis Rheumatol; 2020 Jan; 72(1):78-88. PubMed ID: 31469249
[TBL] [Abstract][Full Text] [Related]
15. C4a anaphylatoxin levels as an indicator of disease activity in systemic lupus erythematosus.
Wild G; Watkins J; Ward AM; Hughes P; Hume A; Rowell NR
Clin Exp Immunol; 1990 May; 80(2):167-70. PubMed ID: 2357842
[TBL] [Abstract][Full Text] [Related]
16. [Components of the classical complement pathway in systemic lupus erythematosus].
Maillet F; Goetz J; Hauptmann G; Clauvel JP; Mery JP; Kahn MF; Kazatchkine M
Presse Med; 1987 Mar; 16(8):378-82. PubMed ID: 2950498
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil chemotaxis and serum chemotactic activity in systemic lupus erythematosus.
Alvarez I; Vazquez JJ; Fontan G; Gil A; Barbado J; Ojeda JA
Scand J Rheumatol; 1978; 7(2):69-74. PubMed ID: 705269
[TBL] [Abstract][Full Text] [Related]
18. Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products.
Lim KL; Jones AC; Brown NS; Powell RJ
Ann Rheum Dis; 1993 Jun; 52(6):429-35. PubMed ID: 8323394
[TBL] [Abstract][Full Text] [Related]
19. Complement abnormalities in multiple myeloma.
Zurlo JJ; Schechter GP; Fries LF
Am J Med; 1989 Oct; 87(4):411-20. PubMed ID: 2679074
[TBL] [Abstract][Full Text] [Related]
20. Complement Alternative Pathway׳s Activation in Patients With Lupus Nephritis.
Song D; Guo WY; Wang FM; Li YZ; Song Y; Yu F; Zhao MH
Am J Med Sci; 2017 Mar; 353(3):247-257. PubMed ID: 28262211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
